Table 2 Characteristics of lipid-lowering therapy in Familial Hypercholesterolemia Phenotype population.
FH-P without cardiovascular disease | FH-P with cardiovascular disease | |||||
|---|---|---|---|---|---|---|
Male N = 5.088 | Female N = 7.033 | P-value | Male N = 1659 | Female N = 919 | P-value | |
Absence of treatment, N, % | 969 (19) | 977 (14) | 0.001 | 49 (3) | 21 (2) | 0.35 |
Low LLT, N, % | 442 (9) | 781 (11) | 0.001 | 57 (3) | 56 (6) | 0.001 |
Moderate LLT; N, % | 2.785 (55) | 4.099 (58) | 628 (38) | 438 (48) | ||
High LLT, N, % | 833 (16) | 1087 (15) | 833 (52) | 369 (40) | ||
Very High LLT, N% | 59 (1) | 89 (1) | 92 (6) | 36 (4) | ||
Statins and ezetimibe; N, % | 184 (4) | 222 (3) | 0.19 | 196 (12) | 86 (9) | 0.07 |
Statin pattern dosea, N, % | Simvastatin 20 1.353 (33) | Simvastatin 20 2.140(36) | 0.003 | Atorvastatin 40. 555 (34) | Atorvastatin 40. 252 (28) | 0.001 |
Simvastatin 40. 784 (19) | Simvastatin 40 1.114 (18) | Simvastatin 20 189 (12) | Simvastatin 20 168 (19) | |||
Atorvastatin 40. 607 (15) | Atorvastatin 40 825 (14) | Atorvastatin 80 237 (15) | Atorvastatin 80 99 (11) | |||
Adherence (MPR) | 0.6 (0.4) | 0.6 (0.3) | 0.001 | 0.8 (0.3) | 0.7 (0.3) | 0.003 |
Patients with LDL-C > 3.36 mmol/L, N, % | 3.612 (71) | 5.275 (75) | 0.001 | 647 (39) | 478 (52) | 0.001 |
Patients with LDL-C > 2.5 mmol/L; N; % | 4.731 (93) | 6.681 (95) | 0.001 | 1.228 (74) | 772 (84) | 0.001 |
Patients with LDL-C > 1.81 mmol/L mg/dL; N; % | 5.037 (99) | 6.963 (99) | 0.1 | 1.626 (98) | 910 (99) | 0.001 |
